Lysophosphatidic Acid Receptor 3 (LPAR3) Peptide
LPAR3
WB
N° du produit ABIN925008
600,00 €
Plus frais de livraison 40,00 € et TVA
50 μg
Destination:
France
Envoi sous 15 à 22 jours ouvrables
Aperçu rapide pour Lysophosphatidic Acid Receptor 3 (LPAR3) Peptide (ABIN925008)
Antigène
LPAR3
(Lysophosphatidic Acid Receptor 3 (LPAR3))
Application
Western Blotting (WB)
-
-
Lysophosphatidic Acid Receptor 3 (LPAR3) peptide
LPAR3 Hôte: Synthetic BP, WB, IHC
-
-
Indications d'application
- For use with EDG-7 (CT) polyclonal antibody (ABIN187789). Incubate antibody neat with at least a 50 fold stoichiometric excess of blocking peptide at 37°C for 20 min (moluclar weights of peptide and antibody are 2.5 kDa and 160 kDa, respectively). Antibody can then be diluted to a concentration suitable for Western blot.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- Provided as 1 mg/ml in PBS.
-
Stock
- -20 °C
-
-
- LPAR3 (Lysophosphatidic Acid Receptor 3 (LPAR3))
-
Sujet
- EDG-7 belongs to a family of G-protein coupled receptors whose ligands are lysophospholipids. The ligand for EDG-7 is lysophospholipid. There are 8 known members of the EDG receptor family and they are implicated in mediating growth related effects such as induction of cellular proliferation, alterations in differentiation and survival and suppression of apoptosis. They also evoke cellular effector functions that are dependent on cytoskeletal responses such as contraction, secretion, adhesion, and chemotaxis. EDG receptors are developmentally regulated and differ in tissue distribution. They couple to multiple types of G proteins to signal through ras and MAP kinase, rho, phospholipase C, and several protein tyrosine kinases. EDG-7 is expressed in prostate as well as other tissues.
Antigène
-
Vous êtes ici:
